Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)
In the post-pandemic COVID-19 period, human activities have returned to normal and
COVID-19 cases are usually mild. However, patients with multiple myeloma (MM) present an …
COVID-19 cases are usually mild. However, patients with multiple myeloma (MM) present an …
Vaccine schedule recommendations and updates for patients with hematologic malignancy post‐hematopoietic cell transplant or CAR T‐cell therapy
G Reynolds, VG Hall, BW Teh - Transplant Infectious Disease, 2023 - Wiley Online Library
Revaccination after receipt of a hematopoietic cell transplant (HCT) or cellular therapies is a
pillar of patient supportive care, with the potential to reduce morbidity and mortality linked to …
pillar of patient supportive care, with the potential to reduce morbidity and mortality linked to …
[HTML][HTML] Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022
Background The COVID-19 pandemic heightened risks for individuals with hematological
malignancies due to compromised immune systems, leading to more severe outcomes and …
malignancies due to compromised immune systems, leading to more severe outcomes and …
Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey
JA van Doesum, J Salmanton-García… - Blood …, 2023 - ashpublications.org
Patients with previous CD19-directed chimeric antigen receptor (CAR) T-cell therapy have a
prolonged vulnerability to viral infections. Coronavirus disease 2019 (COVID-19) has a great …
prolonged vulnerability to viral infections. Coronavirus disease 2019 (COVID-19) has a great …
Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the …
Only few studies have analyzed the efficacy of tixagevimab/cilgavimab to prevent severe
Coronavirus disease 2019 (COVID-19) and related complications in hematologic …
Coronavirus disease 2019 (COVID-19) and related complications in hematologic …
Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with COVID-19; An infectious disease working …
P Ljungman, G Tridello, JL Piñana, F Ciceri… - Frontiers in …, 2023 - frontiersin.org
Introduction COVID-19 has been associated with high morbidity and mortality in allogeneic
hematopoietic stem cell transplant (allo-HCT) recipients. Methods This study reports on 986 …
hematopoietic stem cell transplant (allo-HCT) recipients. Methods This study reports on 986 …
[HTML][HTML] Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings
G Rossi, J Salmanton-García, C Cattaneo… - International Journal of …, 2023 - Elsevier
Objectives Elderly patients with hematologic malignancies face the highest risk of severe
COVID-19 outcomes. The infection's impact on different age groups remains unstudied in …
COVID-19 outcomes. The infection's impact on different age groups remains unstudied in …
COVID-19 vaccination in patients with cancer and patients receiving HSCT or CAR-T therapy: immune response, real-world effectiveness, and implications for the …
VG Hall, BW Teh - The Journal of infectious diseases, 2023 - academic.oup.com
Patients with cancer demonstrate an increased vulnerability for infection and severe disease
by SARS-CoV-2, the causative agent of COVID-19. Risk factors for severe COVID-19 include …
by SARS-CoV-2, the causative agent of COVID-19. Risk factors for severe COVID-19 include …
Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey
Study objectives This study aimed to achieve several key objectives related to patients with
haematological malignancies and COVID-19 who required ICU admission. Firstly, we …
haematological malignancies and COVID-19 who required ICU admission. Firstly, we …
Clinical manifestations and risk factors for COVID-19 and its severity in patients with hematological malignancies
TY Wu, WT Tsai, KH Chen, ST Huang… - Journal of Microbiology …, 2024 - Elsevier
Background Patients with hematological malignancies (HM) were at a high risk of
develo** severe disease from coronavirus disease 2019 (COVID-19). We aimed to assess …
develo** severe disease from coronavirus disease 2019 (COVID-19). We aimed to assess …